Evolus Inc.

May 21, 2019

ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt

May 15, 2019

ALPHAEON Corporation sells 4 million shares in Evolus Inc.

Feb 17, 2018

Evolus Announces Presentation of Phase III European - Canadian Comparative Data

Feb 16, 2018

Evolus Announces Presentation of Phase III Comparative Data of PrabotulinumtoxinA and OnabotulinumtoxinA

Feb 12, 2018

Evolus, Inc. Announces Closing of Initial Public Offering of Common Stock

Feb 07, 2018

Evolus, Inc. Announces Pricing of Initial Public Offering of Common Stock

Jan 09, 2018

Evolus, Inc. Files Registration Statement for Proposed Initial Public Offering

Oct 26, 2017

Evolus Announces Health Canada Acceptance for Review of the New Drug Submission for PrabotulinumtoxinA

Oct 09, 2017

Evolus Announces Presentations of Phase II and Phase III Data of PrabotulinumtoxinA

Jul 20, 2017

Evolus Announces European Medicines Agency Acceptance for Review of the Marketing Authorization Application for DWP-450 Neuromodulator

Jul 19, 2017

Evolus Announces FDA Acceptance for Review of the Biologics License Application for DWP-450 Neuromodulator